|
(1) Intestinal Organoid Models for APC LOH
|
5R21CA208638-02
|
$192,406
|
GIARDINA, CHARLES
|
UNIVERSITY OF CONNECTICUT STORRS
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
2U54CA163071-06
|
$1,427,230
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
3U54CA163071-07S1
|
$48,687
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
3U54CA163071-07S2
|
$85,299
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
3U54CA163071-07S3
|
$47,040
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
5U54CA163071-07
|
$1,619,382
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(2/2) CDU/UCLA Cancer Center Partnership to Eliminate Cancer Health Disparities
|
5U54CA143930-08
|
$704,474
|
FARIAS-EISNER, ROBIN
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
(2/2) CDU/UCLA Cancer Center Partnership to Eliminate Cancer Health Disparities
|
5U54CA143930-09
|
$714,423
|
FARIAS-EISNER, ROBIN
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
(PQ1) Adaptive immune and microbial mechanisms regulating Lynch syndrome penetrance
|
1R01CA231283-01
|
$501,220
|
LIPKIN, STEVEN
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.
|
5R01CA208644-02
|
$377,438
|
CRITTENDEN, MARKA
|
PROVIDENCE PORTLAND MEDICAL CENTER
|
|
(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.
|
5R01CA208644-03
|
$377,438
|
CRITTENDEN, MARKA
|
PROVIDENCE PORTLAND MEDICAL CENTER
|
|
(PQ3) Cellular and Molecular Mechanisms Driving Myeloid Compartment Variation in Human Triple Negative Breast Cancer
|
1R01CA219880-01
|
$697,539
|
PALUCKA, ANNA KAROLINA
|
JACKSON LABORATORY
|
|
(PQ3) Cellular and Molecular Mechanisms Driving Myeloid Compartment Variation in Human Triple Negative Breast Cancer
|
5R01CA219880-02
|
$670,182
|
PALUCKA, ANNA KAROLINA
|
JACKSON LABORATORY
|
|
(PQ4) Novel tools for in vivo study of genetic interactions in cancer progression
|
1R01CA231112-01
|
$576,627
|
CHEN, SIDI
|
YALE UNIVERSITY
|
|
(PQ7)Multi-scale Analysis of Tumor Microenvironment Heterogeneity
|
1R01CA208735-01A1
|
$729,393
|
FELSHER, DEAN
|
STANFORD UNIVERSITY
|
|
(PQ7)Multi-scale Analysis of Tumor Microenvironment Heterogeneity
|
5R01CA208735-02
|
$730,063
|
FELSHER, DEAN
|
STANFORD UNIVERSITY
|
|
(PQA-4) Organoid Omics To Detect And Defeat Ductal Pancreatic Cancer
|
5R01CA190092-04
|
$552,684
|
TUVESON, DAVID
|
COLD SPRING HARBOR LABORATORY
|
|
(PQA1)The Molecular Mechanisms Underlying Effects of Aspirin on Colorectal Cancer
|
5R01CA184820-04
|
$386,650
|
DUBOIS, RAYMOND
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
(PQB-4) Single cell analysis strategy for monitoring drug responses of tumors
|
5R01CA190122-04
|
$571,080
|
TIAN, QIANG
|
INSTITUTE FOR SYSTEMS BIOLOGY
|
|
(PQC-5) Zwitterionic NIR/Zr-89 Agents for Prostate Cancer Staging and Treatment
|
5R01CA185457-04
|
$640,378
|
FRANGIONI, JOHN
|
CURADEL, LLC
|
|
0021.0001 CG 425 METAVIVOR
|
261200800001E
|
$319,219,481
|
UNKNOWN, UNKNOWN
|
LEIDOS BIOMEDICAL RESEARCH, INC.
|
|
0021.0001 CG 425 METAVIVOR
|
261200800001E
|
$319,219,481
|
UNKNOWN, UNKNOWN
|
LEIDOS BIOMEDICAL RESEARCH, INC.
|
|
1/2 SDSU/UCSD Cancer Center Comprehensive Partnership
|
5U54CA132379-08
|
$1,258,708
|
MARTINEZ, MARIA
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
1/2 SDSU/UCSD Cancer Center Comprehensive Partnership
|
5U54CA132379-09
|
$1,304,869
|
MARTINEZ, MARIA
|
UNIVERSITY OF CALIFORNIA, SAN DIEGO
|
|
1/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership
|
5P20CA192973-04
|
$191,836
|
MANNE, UPENDER
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
2/2 Langston University-UNTHSC Partnership for Cancer Research and Education
|
1P20CA233355-01
|
$255,958
|
VISHWANATHA, JAMBOOR
|
UNIVERSITY OF NORTH TEXAS HLTH SCI CTR
|
|
2/2 NCCU-LCCC Partnership in Cancer Research
|
5U54CA156733-08
|
$919,471
|
EARP, HENRY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
2/2 NCCU-LCCC Partnership in Cancer Research
|
5U54CA156733-09
|
$1,003,901
|
EARP, HENRY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
2/2 Ponce School of Medicine-Moffitt Cancer Center Partnership
|
2U54CA163068-06
|
$1,656,304
|
MUNOZ-ANTONIA, TERESITA
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
2/2 Ponce School of Medicine-Moffitt Cancer Center Partnership
|
5U54CA163068-07
|
$1,751,252
|
MUNOZ-ANTONIA, TERESITA
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
2/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership
|
5P20CA192976-04
|
$144,556
|
MISHRA, MANOJ
|
ALABAMA STATE UNIVERSITY
|
|
2/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama Ca Ctr Partnership
|
5U54CA118623-12
|
$407,680
|
TROY, ROBERTA
|
TUSKEGEE UNIVERSITY
|
|
2/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama Ca Ctr Partnership
|
5U54CA118623-13
|
$1,101,004
|
TROY, ROBERTA
|
TUSKEGEE UNIVERSITY
|
|
3/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama Ca Ctr Partnership
|
5U54CA118948-13
|
$1,170,535
|
MANNE, UPENDER
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
A 3D Model of the Perivascular Niche to Investigate Glioblastoma Invasion
|
1F31CA228317-01
|
$39,703
|
WOLF, KAYLA
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
|
A DRUGGABLE CHROMATIN MODIFIER PATHWAY IN HCC
|
1R21CA229927-01
|
$218,588
|
WAJAPEYEE, NARENDRA
|
YALE UNIVERSITY
|
|
A highly specific NIRF/PET probe for the detection of cancer and metastases
|
1R43CA210854-01A1
|
$224,958
|
Yang, Xinlin
|
IMOL RADIOPHARMACEUTICALS, LLC
|
|
A Microfluidics Approach to Investigate Tumor Cell Trafficking in Bone Marrow
|
1F32CA210540-01A1
|
$58,326
|
GLASER, DREW
|
UNIVERSITY OF CALIFORNIA AT DAVIS
|
|
A Microfluidics Approach to Investigate Tumor Cell Trafficking in Bone Marrow
|
5F32CA210540-02
|
$61,174
|
GLASER, DREW
|
UNIVERSITY OF CALIFORNIA AT DAVIS
|
|
A multi-fluorescent intravital microscopy approach to study osteosarcoma
|
7R21CA208618-02
|
$176,380
|
INTINI, GIUSEPPE
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
A multiplexed approach to improve tumoral targeting and chemotherapeutic treatment
|
1R01CA222802-01A1
|
$412,139
|
LAW, BENEDICT
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
A new imaging approach to radiotherapy planning for lung cancer
|
5R01CA193050-03
|
$535,497
|
RIZI, RAHIM
|
UNIVERSITY OF PENNSYLVANIA
|
|
A NOVEL EXTRACELLULAR AND INTRACELLULAR TREATMENT PARADIGM FOR ERADICATING CANCER
|
5F30CA189435-04
|
$49,044
|
SOM, AVIK
|
WASHINGTON UNIVERSITY
|
|
A Novel Immunotherapy Targeting Cancer Stem Cells for the Treatment of Triple-Negative Breast Cancer
|
1R44CA224835-01A1
|
$298,864
|
PERICLE, FEDERICA
|
AGILVAX, INC.
|
|
A novel small molecule FL7N-1 for treating pediatric cancer retinoblastoma
|
1R43CA221389-01A1
|
$224,919
|
LING, XIANG
|
CANGET BIOTEKPHARMA, LLC
|
|
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma
|
1R44CA217591-01
|
$621,000
|
KAHN, STUART
|
SYNTRIX BIOSYSTEMS, INC.
|
|
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma
|
4R44CA217591-02
|
$1,125,311
|
KAHN, STUART
|
SYNTRIX BIOSYSTEMS, INC.
|
|
A Phase I Dose-escalation Study of Intraperitoneal CYN101 as Consolidation Immunotherapy in Women with Residual or Recurrent Ovarian Cancer Status after Chemotherapy
|
5R44CA206606-02
|
$1,004,186
|
WINRAM, SCOTT
|
CYNVEC, LLC
|
|
A Quality Control Program for Quantitative MRI Data Acquisition and Analysis in Multi-site Clinical Trials
|
1R44CA235820-01
|
$224,422
|
KARAULANOV, TODOR
|
QALIBREMD, INC.
|
|
A simple assay system for rapid detection of circulating tumor cells
|
3R41CA183428-01A1S2
|
$50,000
|
HONG, BIN
|
TELOVISION, LLC
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|